Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. More Details
+ 3 more risks
Weak fundamentals or lack of information.
Share Price & News
How has VentriPoint Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VPT is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: VPT's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of Canadian stocks.
7 Day Return
CA Medical Equipment
1 Year Return
CA Medical Equipment
Return vs Industry: Insufficient data to determine how VPT performed against the Canadian Medical Equipment industry.
Return vs Market: Insufficient data to determine how VPT performed against the Canadian Market.
Long-Term Price Volatility Vs. Market
How volatile is VentriPoint Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is VentriPoint Diagnostics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether VentriPoint Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VentriPoint Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is VentriPoint Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VentriPoint Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has VentriPoint Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VPT is currently unprofitable.
Growing Profit Margin: VPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VPT is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare VPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VPT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (21.2%).
Return on Equity
High ROE: VPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is VentriPoint Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: VPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: VPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: VPT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: VPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VPT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VPT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.6% each year
What is VentriPoint Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VPT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
George Adams (68 yo)
Dr. George Adams, B.A.Sc., M.A.Sc., Ph.D., ICD.D., is Managing Director at Cell MedX Corp. He serves as Chief Executive Officer of VentriPoint Diagnostics Ltd. and served as Acting Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD166.27K) is about average for companies of similar size in the Canadian market ($USD157.18K).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
Experienced Management: VPT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: VPT's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VPT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 91.3%.
VentriPoint Diagnostics Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: VentriPoint Diagnostics Ltd.
- Ticker: VPT
- Exchange: TSXV
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$57.342m
- Shares outstanding: 133.35m
- Website: https://www.ventripoint.com
- VentriPoint Diagnostics Ltd.
- 2 Sheppard Avenue East
- Suite 605
- M2N 5Y7
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System, a med...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/14 22:20|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.